Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options
Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection.
The Sorrento Analyst
H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $24 price target.
Comment: Every placement these guys do seems to sour. Time for an investigation?
Competing Comment: Every placement is subject to naked short selling pressure, without an investigation you cannot know for sure. Some companies do have histories. HCWainwreight appears to be one of them.
